CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
about
Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating AspirinPathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variantsDrug interactions--principles, examples and clinical consequencesCardiovascular pharmacogenomics: current status and future directionsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysisApplication of routine electronic health record databases for pharmacogenetic researchStroke genetics: prospects for personalized medicinePharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?The Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityImproving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocolsUse of genetic data to guide therapy in arterial disease.Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary interventionGenomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of ClopidogrelApplied pharmacogenomics in cardiovascular medicineGuided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.Antiplatelet drug interactions with proton pump inhibitorsMutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionPharmacogenetic selection of volunteers increases stringency of bioequivalence studies; the case of clopidogrelPharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Understanding and preventing drug-drug and drug-gene interactions.Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies.CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.Personalizing health care: feasibility and future implications.Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.Pharmacogenomic assessment of Mexican and Peruvian populations.Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary interventionClopidogrel: a case for indication-specific pharmacogenetics.Personalized medicine: is it a pharmacogenetic mirage?Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Genotype-based clinical trials in cardiovascular disease.Personalised medicine: not just in our genes.
P2860
Q22306342-B641CE1C-11AE-476A-9384-6A820896E8A3Q24273409-5CCADD41-4997-455C-99FC-4156B0161A62Q24599421-23EA64C2-00EE-45D0-A7A5-97AE61431CDAQ26801183-DC03633C-EF99-4805-8ECF-AEB4377A6C3DQ26801867-47111777-ACF9-4ACC-9E59-AA235A715057Q26822796-448E1302-E5F1-432D-B4EB-1067E3127B42Q26823542-CA9AD267-DE31-498E-85A6-06B9C86C8779Q26849714-1DB50FDA-4D5F-4958-B549-1423A4FF2942Q26864747-C4914B70-5FB5-4C29-815B-4B43345E6938Q27006885-311C5FAE-25B7-499F-BA5A-86A728ABDD97Q27022443-18CCD0D7-2877-4BE6-927F-B9C659466340Q28080256-E92F4C37-AD29-4C94-A58D-4A8FCA894C29Q28655983-6576F16F-EC28-4F6E-9CB4-66CCD2CEE830Q30978916-2275E46E-A8AE-49C7-83F0-21E594FC59BAQ33365061-A0306058-F483-48B4-9FBB-68FBAFD4A4B5Q33426570-7A9D955C-DC94-45BE-AF82-AEA2A8E6D8DAQ33837665-C5132ECB-515B-4D6E-BE92-C17693D560A8Q33846255-1DA7964E-D4F9-4D20-901E-ABF8B893ADE0Q33863833-4EB4F273-0B2C-46FD-9CF3-9B0A2504C22CQ33923341-89DE0601-C578-4CD1-BDF2-7F324EEB07ACQ33948811-227E2AF8-27D4-4C33-83C6-0965B9D34DFBQ34108764-A5412F6D-0033-4ED5-AB90-37D2E31B3EECQ34166239-75BCE4BE-18E9-49B8-826E-2267C1BC4456Q34228913-7FEE10A0-C235-4385-9E78-4D3A2C2F89B8Q34307589-5CCECEA6-3D8B-4271-9168-4EC6507AAAFAQ34415944-9F150DF3-4FFE-435F-A84F-4A13095FA7B3Q34631709-98640024-82B1-490F-8BB0-73014CC47E8EQ34649009-3167F6CC-BBCC-427A-8468-39CDD7EE955FQ34938911-7AB8169C-9A28-485E-A690-75E80ACEEAD5Q34975032-9001C94A-A5DE-41CF-8227-5F2FE1453445Q34981428-29994C44-4B21-4FC6-BE7D-B90AD2821916Q35009604-3602F42A-EEB9-40EC-8E92-274517E93B70Q35860284-0BE78564-36C4-4D31-B483-BC9E8109EB23Q35890226-15B071CC-4FCD-46EE-A550-3D74E4E68B7BQ35959359-7920372A-7119-4CCC-8B04-E47D1AC5F01FQ36055186-16EAA42F-A7A3-483A-96CD-A54C0850CCB9Q36336007-366FA438-F7BD-487E-AAF2-B675C17CAA89Q36391044-BBA8A1E8-5180-437E-80BF-E53EA80CE558Q36393911-8E461A8B-9E8A-44B8-87D2-31C5CFFB6B28Q36396620-5FF6F2B2-3B0F-4ECA-99D9-FFD5EF49C62B
P2860
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@en
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@nl
type
label
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@en
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@nl
prefLabel
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@en
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@nl
P2093
P921
P356
P1476
CYP2C19 genotype, clopidogrel ...... atic review and meta-analysis.
@en
P2093
Juan P Casas
Michael V Holmes
Pablo Perel
P304
P356
10.1001/JAMA.2011.1880
P407
P577
2011-12-01T00:00:00Z